(Q34636135)

3 August 2017

1 reference

title

The safety of statins in clinical practice (English)

1 reference

3 August 2017

Jane Armitage

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

3 August 2017

1 reference

3 August 2017

volume

370

1 reference

3 August 2017

issue

9601

1 reference

3 August 2017

page(s)

1781-1790

1 reference

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

1 reference

7 January 2021

A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Withdrawal of cerivastatin from the world market

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Statin safety: an appraisal from the adverse event reporting system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Report of the Conference on Low Blood Cholesterol: Mortality Associations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Ischemic heart disease and cholesterol. Safety of cholesterol reduction remains in doubt

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Statin-associated myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Mechanistic studies on metabolic interactions between gemfibrozil and statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Efficacy and long-term adverse effect pattern of lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Statin safety: lessons from new drug applications for marketed statins.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

The issue of statin safety: where do we stand?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Statin safety: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Serum alanine aminotransferase in skeletal muscle diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

1 reference

7 January 2021

Defining patient risks from expanded preventive therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Drug-induced hepatotoxicity: 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Experience with statin use in patients with chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Drug-related hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

1 reference

7 January 2021

Rhabdomyolysis: an evaluation of 475 hospitalized patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Central nervous system and limb anomalies in case reports of first-trimester statin exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

The role of maternal toxicity in lovastatin-induced developmental toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Pregnancy outcomes after maternal exposure to simvastatin and lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Statin drugs and congenital anomalies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Effect of lipid reduction on the progression of renal disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Rosuvastatin-induced arrest in progression of renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Statins for improving renal outcomes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

The relationship between cholesterol and survival in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Statin use in heart failure: a cause for concern?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Sleep disturbance and HMG CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Plasma cholesterol and depressive symptoms in older men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Low cholesterol concentrations and severe depressive symptoms in elderly people

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Statin-associated memory loss: analysis of 60 case reports and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Statins and risk of polyneuropathy: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Statin Use, Bone Mineral Density, and Fracture Risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Statins and the risk of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960716-8

7 January 2021

10.1016/S0140-6736(07)60716-8

Identifiers

DOI

1 reference

3 August 2017

1 reference